FGFR2 and cholangiocarcinoma: Prospective investigations of FGFR2 fusion-positive cholangiocarcinoma have established standardized protocols: baseline detection followed by initial assessment at 4 weeks of treatment, with subsequent monitoring every 8 weeks.